UCB (ENXTBR:UCB) - Stock Price, News & Analysis

UCB Stock Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases.

UCB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	1/6
Financial Health	4/6
Dividends	4/6

Rewards

Trading at 63.3% below our estimate of its fair value

Earnings are forecast to grow 29.36% per year

Risk Analysis

Profit margins (6.5%) are lower than last year (15.2%)

UCB SA Competitors

Financière de Tubize

ENXTBR:TUB

€3.1b

Eisai

TSE:4523

JP¥2.4t

Royalty Pharma

NasdaqGS:RPRX

US$15.8b

Yunnan Baiyao GroupLtd

SZSE:000538

CN¥94.8b

Price History & Performance

Summary of all time highs, changes and price drops for UCB
Historical stock prices
Current Share Price	€82.12
52 Week High	€88.80
52 Week Low	€67.58
Beta	0.33
1 Month Change	-0.024%
3 Month Change	-1.86%
1 Year Change	18.26%
3 Year Change	-16.02%
5 Year Change	6.10%
Change since IPO	1,697.25%

Is UCB (EBR:UCB) Using Too Much Debt?

Aug 07

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Jun 02

Recent updates

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 54% Above Its Share Price

Feb 10

What Makes UCB SA (EBR:UCB) A Great Dividend Stock?

Jan 20

Is UCB SA (EBR:UCB) Popular Amongst Institutions?

Jan 07

UCB (EBR:UCB) Is Growing Earnings But Are They A Good Guide?

Dec 23

With EPS Growth And More, UCB (EBR:UCB) Is Interesting

Dec 04

UCB SA's (EBR:UCB) Share Price Not Quite Adding Up

Sep 17

UCB's (EBR:UCB) Earnings Are Growing But Is There More To The Story?

Aug 31

Here's What UCB SA's (EBR:UCB) Shareholder Ownership Structure Looks Like

Aug 06

Shareholder Returns

	UCB	BE Pharmaceuticals	BE Market
7D	-2.5%	-2.0%	-1.1%
1Y	18.3%	18.1%	9.0%

Return vs Industry: UCB matched the Belgian Pharmaceuticals industry which returned 18% over the past year.

Return vs Market: UCB exceeded the Belgian Market which returned 6.8% over the past year.

Price Volatility

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	4.9%
Market Average Movement	3.3%
10% most volatile stocks in BE Market	6.8%
10% least volatile stocks in BE Market	2.1%

Stable Share Price: UCB is less volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: UCB's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1925	8,600	Jean-Christophe Tellier	https://www.ucb.com

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus.

UCB SA Fundamentals Summary

How do UCB's earnings and revenue compare to its market cap?
UCB fundamental statistics
Market Cap	€15.58b
Earnings (TTM)	€332.00m
Revenue (TTM)	€5.11b

46.9x

P/E Ratio

3.0x

P/S Ratio

Is UCB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
UCB income statement (TTM)
Revenue	€5.11b
Cost of Revenue	€1.63b
Gross Profit	€3.48b
Other Expenses	€3.15b
Earnings	€332.00m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Feb 28, 2024

Earnings per share (EPS)	1.75
Gross Margin	68.09%
Net Profit Margin	6.50%
Debt/Equity Ratio	30.3%

How did UCB perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

76%

Payout Ratio

UCB Stock Overview

Rewards

Risk Analysis

UCB SA Competitors

ENXTBR:TUB

€3.1b

TSE:4523

JP¥2.4t

NasdaqGS:RPRX

US$15.8b

SZSE:000538

CN¥94.8b

Price History & Performance

Recent News & Updates

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Recent updates

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of €0.91 per share

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

Director has left the company

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Is UCB (EBR:UCB) Using Too Much Debt?

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs